HONG KONG, Aug. 24, 2023 /PRNewswire/ — Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately RMB3,783.8 million, up 22.3% on a yearly basis. Gross profit was approximately RMB3,201.6…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.